Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.

Authors not listed

Ohr Pharmaceutical Inc. · 2012

Abstract

The purpose of this study is to evaluate the safety and efficacy of topical ophthalmic squalamine lactate eye drops in treating patients with neovascular age-related macular degeneration (wet AMD), a degenerative retinal eye disease that causes a progressive, irreversible, severe loss of central vision.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-12 MST

Cite this

APA
Anonymous. (2012). Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD. <em>Ohr Pharmaceutical Inc.</em>. https://clinicaltrials.gov/study/NCT01678963
Vancouver
Anonymous. Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD. Ohr Pharmaceutical Inc.. 2012.
BibTeX
@misc{anon2012PhaseI, title = {Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.}, author = {Anonymous}, journal = {Ohr Pharmaceutical Inc.}, year = {2012}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings